The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://finniangswc124337.blogaritma.com/39649023/retatrutide-and-nicotinamide-adenine-dinucleotide-a-triple-threat-system-to-general-health